Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam (GQM10)

NCT03765437 PHASE3 COMPLETED

The primary objective of this study is to describe the safety of the Quadrivalent Influenza Vaccine (QIV). Safety is assessed throughout the study period, and includes solicited injection site and systemic reactions (Day 0 to Day 7 post-vaccination); unsolicited adverse events up to Day 28, and serious adverse events occurring throughout the study.

Details

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Phase	PHASE3
Status	COMPLETED
Enrolment	230
Start date	Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Mar 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza

Interventions

• Quadrivalent Influenza Vaccine

Countries

Vietnam